Sarepta Therapeutics, Inc.
SRPT
$19.20
$0.070.37%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 730.80M | 442.93M | 399.36M | 611.09M | 744.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 730.80M | 442.93M | 399.36M | 611.09M | 744.86M |
| Cost of Revenue | 119.05M | 724.04M | 369.67M | 356.95M | 154.88M |
| Gross Profit | 611.76M | -281.11M | 29.69M | 254.14M | 589.98M |
| SG&A Expenses | 108.95M | 128.30M | 91.89M | 137.90M | 133.63M |
| Depreciation & Amortization | 691.00K | 677.00K | 677.00K | 667.00K | 601.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 372.37M | 853.02M | 462.24M | 495.51M | 1.05B |
| Operating Income | 358.43M | -410.08M | -62.88M | 115.58M | -300.39M |
| Income Before Tax | 343.17M | -278.30M | -194.05M | 153.64M | -383.52M |
| Income Tax Expenses | 12.22M | 4.55M | -14.10M | -43.25M | 63.99M |
| Earnings from Continuing Operations | 330.96M | -282.85M | -179.95M | 196.89M | -447.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 330.96M | -282.85M | -179.95M | 196.89M | -447.51M |
| EBIT | 358.43M | -410.08M | -62.88M | 115.58M | -300.39M |
| EBITDA | 369.03M | -404.83M | -44.43M | 126.42M | -290.41M |
| EPS Basic | 3.15 | -2.70 | -1.80 | 2.01 | -4.60 |
| Normalized Basic EPS | 2.05 | -2.52 | -0.40 | 0.73 | -1.89 |
| EPS Diluted | 2.88 | -2.70 | -1.80 | 1.89 | -4.60 |
| Normalized Diluted EPS | 1.76 | -2.52 | -0.40 | 0.67 | -1.89 |
| Average Basic Shares Outstanding | 104.99M | 104.79M | 100.24M | 98.01M | 97.36M |
| Average Diluted Shares Outstanding | 121.92M | 104.79M | 100.24M | 106.62M | 97.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |